Χώρα: Καναδάς
Γλώσσα: Αγγλικά
Πηγή: Health Canada
THEOPHYLLINE
AA PHARMA INC
R03DA04
THEOPHYLLINE
100MG
TABLET (EXTENDED-RELEASE)
THEOPHYLLINE 100MG
ORAL
100 TABLETS
Prescription
RESPIRATORY SMOOTH MUSCLE RELAXANTS
Active ingredient group (AIG) number: 0103582002; AHFS:
APPROVED
2019-04-30
_ _ _ _ _Pr_ _AA-THEO LA _ _Page 1 of 24_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR AA-THEO LA Theophylline Anhydrous Sustained-Release Tablets, 100, 200, 300 mg and Oral House Standard Bronchodilator ATC Code: R03DA04 AA PHARMA INC. 1165 Creditstone Road, Unit#1 Vaughan, Ontario L4K 4N7 Date of Initial Authorization: DEC 31, 1993 Date of Revision: January 13, 2022 Submission Control Number: 254884 _ _ _ _ _Pr_ _AA-THEO LA _ _Page 2 of 24_ RECENT MAJOR LABEL CHANGES 1 Indications 12/2021 3 Serious Warnings and Precautions Box 12/2021 7 Warnings and Precautions 12/2021 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. TABLE OF CONTENTS ................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................4 1 INDICATIONS ................................................................................................................4 1.1 Pediatrics ............................................................................................................4 1.2 Geriatrics.............................................................................................................4 2 CONTRAINDICATIONS ...................................................................................................4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ..............................................................4 4 DOSAGE AND ADMINISTRATION...................................................................................5 4.1 Dosing Considerations .........................................................................................5 4.2 Recommended Dose and Dosage Adjustment.......................................................5 4.4 Administration.....................................................................................................5 5 OVERDOSAGE ................................. Διαβάστε το πλήρες έγγραφο